DailyMed
Cure8 regulatory brief
DailyMed label update for CIMZIA
Medications
Certolizumab
Anti-TNF
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Crohn's disease
Why This Matters
This is an official label (prescribing information) update for CIMZIA (certolizumab pegol), a TNF blocker used to treat Crohn's disease. Label changes can affect dosing, safety warnings, and monitoring that matter to patients and clinicians.
Who Should Pay Attention
Adult patients with Crohn's disease or other indications treated with CIMZIA; clinicians who prescribe or monitor biologic therapy; patients on biologics or considering starting certolizumab.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Source depthMetadata only
What To Know
This is the product prescribing information for CIMZIA (certolizumab pegol).
The label includes boxed warnings about serious infections and malignancy seen with TNF blockers, dosing regimens for Crohn's disease (including induction and maintenance schedules), recommended testing and monitoring (for latent TB, hepatitis B, and infections), contraindications, common adverse reactions, and guidance on vaccination and concomitant immunosuppressive use.
If you are taking or prescribing CIMZIA, review the full label for details on dosing by indication, specific safety warnings (including infection and malignancy risks), and laboratory/monitoring recommendations. This summary is grounded in the DailyMed prescribing information text provided on the linked page.
Keep In Mind
This content is the drug's prescribing information (DailyMed). It is the manufacturer/regulatory label text rather than a clinical study report; consult your clinician for personalized medical decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedNov 2, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Adalimumab May Help Maintain Remission in Crohn's Disease - Medscape
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...